4-1BB (CD137) in anticancer chimeras

4-1BB (CD137, TNFRSF9) mediates costimulatory signals important for activation and persistence of cytotoxic T lymphocytes. In this issue of JEM, Oda et al. (https://doi.org/10.1084/jem.20191166) report on a chimeric construction encompassing extracellular Fas and intracellular 4-1BB to dramatically...

Descripción completa

Detalles Bibliográficos
Autores principales: Melero, Ignacio, Berraondo, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Insights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549314/
https://www.ncbi.nlm.nih.gov/pubmed/33147322
http://dx.doi.org/10.1084/jem.20201562
_version_ 1783592773521244160
author Melero, Ignacio
Berraondo, Pedro
author_facet Melero, Ignacio
Berraondo, Pedro
author_sort Melero, Ignacio
collection PubMed
description 4-1BB (CD137, TNFRSF9) mediates costimulatory signals important for activation and persistence of cytotoxic T lymphocytes. In this issue of JEM, Oda et al. (https://doi.org/10.1084/jem.20191166) report on a chimeric construction encompassing extracellular Fas and intracellular 4-1BB to dramatically improve adoptive T cell therapy.
format Online
Article
Text
id pubmed-7549314
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-75493142021-06-07 4-1BB (CD137) in anticancer chimeras Melero, Ignacio Berraondo, Pedro J Exp Med Insights 4-1BB (CD137, TNFRSF9) mediates costimulatory signals important for activation and persistence of cytotoxic T lymphocytes. In this issue of JEM, Oda et al. (https://doi.org/10.1084/jem.20191166) report on a chimeric construction encompassing extracellular Fas and intracellular 4-1BB to dramatically improve adoptive T cell therapy. Rockefeller University Press 2020-10-08 /pmc/articles/PMC7549314/ /pubmed/33147322 http://dx.doi.org/10.1084/jem.20201562 Text en © 2020 Melero and Berraondo http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Insights
Melero, Ignacio
Berraondo, Pedro
4-1BB (CD137) in anticancer chimeras
title 4-1BB (CD137) in anticancer chimeras
title_full 4-1BB (CD137) in anticancer chimeras
title_fullStr 4-1BB (CD137) in anticancer chimeras
title_full_unstemmed 4-1BB (CD137) in anticancer chimeras
title_short 4-1BB (CD137) in anticancer chimeras
title_sort 4-1bb (cd137) in anticancer chimeras
topic Insights
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549314/
https://www.ncbi.nlm.nih.gov/pubmed/33147322
http://dx.doi.org/10.1084/jem.20201562
work_keys_str_mv AT meleroignacio 41bbcd137inanticancerchimeras
AT berraondopedro 41bbcd137inanticancerchimeras

Ejemplares similares